Envafolimab is named as an intervention in 21 current clinical trials in our China register. 14 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is 3D Medicines (Sichuan) Co., Ltd (4). The most-studied condition is Non-small Cell Lung Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non-small Cell Lung Cancer | 2 |
| Rectal Cancer | 2 |
| Hepatocellular Carcinoma | 2 |
| Solid Tumor | 2 |
| Advanced Biliary Tract Cancers | 1 |
| Colon Neoplasm | 1 |
| Non Small Cell Lung Cancer | 1 |
| Lung Neoplasms | 1 |
| Prostate Cancer | 1 |
| CDK12 Gene Mutation | 1 |
| Solid Tumors | 1 |
| Renal Cell Carcinoma | 1 |
| Metastatic Gastrointestinal Stromal Tumors (GIST) | 1 |
| Gastric Cancer | 1 |
| GIST - Gastrointestinal Stromal Tumor | 1 |
| KIT Gene Mutation | 1 |
| Soft Tissue Sarcoma | 1 |
| Metastatic Colorectal Cancer (CRC) | 1 |
| Advanced Refractory Solid Tumors | 1 |
| Locally Advanced Nasopharyngeal Carcinoma | 1 |
| Envafolimab | 1 |
| Induction Chemotherapy | 1 |
| PD-L1 | 1 |
| Limited-stage Small Cell Lung Cancer (LS-SCLC) | 1 |
| ICC | 1 |
| Advanced Cancer | 1 |
| Biliary Tract Neoplasms | 1 |
| Lead sponsor | Trials |
|---|---|
| 3D Medicines (Sichuan) Co., Ltd. | 4 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Sun Yat-sen University | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Guangdong Provincial People's Hospital | 1 |
| The First People's Hospital of Lianyungang | 1 |
| Tianjin Medical University Second Hospital | 1 |
| ๆฑ ็ | 1 |
| Peking University | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Jian Li | 1 |
| Sir Run Run Shaw Hospital | 1 |
| Anhui Provincial Hospital | 1 |
| Second Affiliated Hospital of Soochow University | 1 |
| Peking University Cancer Hospital & Institute | 1 |
+ 1 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 21 | 14 |
A trial with sites in more than one country appears in each of those registers.
21 current trials in our China register name Envafolimab (also registered as Anti-PD-L1 Monoclonal Antibody) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 14 of the 21 trials are recruiting: 14 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
3D Medicines (Sichuan) Co., Ltd (4), Second Affiliated Hospital, Zhejiang University, School of Medicine (2), Sun Yat-sen University (2) and Tianjin Medical University Cancer Institute and Hospital (1), among 16 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Envafolimab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Envafolimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Envafolimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.